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Background: It is widely recognized that health-related quality of life (HRQL) is impaired in patients with Chronic
Obstructive Pulmonary Disease (COPD), but there is a lack of research on longitudinal associations of COPD and
HRQL. This study examined the effects of COPD in early stages of disease on HRQL over ten years in a working-age
general population setting in Southern Germany while considering the influence of common comorbidities.
Methods: In the population-based KORA F4 study (2006–08) 1,321 participants aged 41–61 years performed spirometry
and reported information on HRQL (measured by the generic SF-12) and comorbidities. For the same participants,
HRQL information was available seven years before and three years after the lung function test from the previous S4
(1999–2001) and the F4L follow-up study (2010). Using linear mixed models, the physical and mental component
summary scores (PCS-12 / MCS-12) of the SF-12 were compared over time between COPD groups.
Results: 7.8% of participants were classified as having COPD (according to the LLN definition and the Global
Lungs Initiative), 59.4% of them in grade 1. Regression models showed a negative cross-sectional association of
COPD grade 2+ with PCS-12 which persisted when comorbidities were considered. Adjusted mean PCS-12 scores
for the COPD grade 2+ group were reduced (−3.5 (p = 0.008) in F4, −3.3 (p = 0.014) in S4 and −4.7 (p = 0.003) in
F4L) compared to the group without airflow limitation. The size of the COPD effect in grade 2+ was similar to the
effect of myocardial infarction and cancer. Over ten years, a small decline in PCS-12 was observed in all groups.
This decline was larger in participants with COPD grade 2+, but insignificant. Regarding MCS-12, no significant
cross-sectional or longitudinal associations with COPD were found.
Conclusion: Despite small HRQL differences between COPD patients in early disease stages and controls and
small changes over ten years, our results indicate that it is important to prevent subjects with airflow limitation
from progression to higher grades. Awareness of HRQL impairments in early stages is important for offering early
interventions in order to maintain high HRQL in COPD patients.
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Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality worldwide. As
it is projected to be the fourth leading cause of death in
2030 [1] COPD is a major global public health problem
and responsible for increased healthcare utilization and
costs [2].
The heterogeneous disease, which in high- and middle-
income countries is mainly caused by tobacco smoking,
is characterized by an airflow limitation which is not
fully reversible, usually progressive and accompanied by
a chronic cough, sputum production and dyspnea. Fur-
thermore, acute exacerbations contribute to the overall
severity of disease as these episodes are accompanied
by worsened symptoms and associated with increased
decline in lung function. Comorbid conditions and sys-
temic or extrapulmonary consequences are frequent in
COPD patients, particularly at higher grades, and their
importance has been increasingly recognized in recent
years. Cardiovascular, metabolic, mental, musculoskel-
etal disorders and cancer are the most common comor-
bidities and influence disease outcomes [3,4].
Characteristics of COPD and its concomitant phenom-
ena impose a burden on patients. Health-related quality
of life (HRQL) as an important patient-reported out-
come measure in COPD has received increased interest
in the recent past. A number of studies have examined
health-related quality of life in COPD patients in stable
disease or during acute exacerbations using both generic
and disease-specific instruments and tried to quantify
the impact of the disease on patients [5].
While disease-specific instruments such as the St
George’s Respiratory Questionnaire (SGRQ) [6,7] are de-
signed to capture the specific aspects associated with a
particular disease, generic instruments such as the Short
Form 12 Health Survey Questionnaire (SF-12) measure
overall health states. Therefore, they are more suitable
to assess the impact of comorbid conditions, and they
allow comparisons across patients with different diseases
and with the general population.
Many of the studies employing generic instruments
such as the SF-12 or the EuroQol 5 dimension (EQ-5D)
only include patients with moderate or severe COPD
[8-10]. However, mild COPD is the most frequent stage
of the disease, with a prevalence of 7.4% in Germany in
those aged 40 and above, while the prevalence of COPD
grades 2 and 3 is estimated to be 5.0% and 0.8% respect-
ively [11].
Only few studies have compared HRQL in COPD pa-
tients with values in healthy controls and included early
disease stages which are often undiagnosed. A recent
cross-sectional analysis based on data from the inter-
national Burden of Obstructive Lung Disease (BOLD)
study found that subjects with COPD had lower physicaland mental HRQL scores than subjects without COPD
[12]. It also showed an increasing negative impact on
health status with increasing disease severity. Subjects
with grade 1 COPD had a similar health status to sub-
jects without airflow limitation.
There is a lack of studies investigating the longitu-
dinal impact of COPD on HRQL while considering co-
morbidities which also impact health status. Most
studies focus on HRQL changes after pharmacological
and non-pharmacological interventions in selected pa-
tients groups [13-15].
Since information about the progression of HRQL in
early stages of COPD is scarce, the aim of this study was
to compare HRQL development over a ten year period
in patients with early COPD stages and in healthy con-




This study uses data from a standardized lung function
test (performed in the F4 sub-cohort) and investigates
the relationship between lung function and HRQL which
was measured simultaneously, seven years before (S4 co-
hort) and three years after (F4L cohort) the lung func-
tion test.
Study population
The present study was based on data from the
population-based KORA (“Cooperative Health Research
in the Augsburg Region”) research, a platform for health
surveys and subsequent follow-up studies in the fields of
epidemiology, health economics and health services re-
search in Southern Germany. Data from the S4 study
from the years 1999 to 2001 and its two follow-up stud-
ies F4 (2006–2008) and F4L (2010) were used covering
an observation period for HRQL of 10 years.
The KORA S4 study randomly selected a representa-
tive sample of 6,640 adults of German nationality aged
25–74 years in the city of Augsburg and the two adja-
cent administrative districts from population registries.
Of those, 4,261 participated in the baseline examination
S4. In the first follow-up examination F4 3,080 partici-
pants (72%) were re-examined after seven years. In the
F4 follow-up, a subsample (n = 1,321) aged 41–61 years
as per reference date (35–54 years at baseline) per-
formed standardized spirometry. Three years later, the
F4L study re-examined 79% (n = 1,051) of this subsample
(Figure 1).
In all KORA studies, participants performed standard-
ized computer-assisted interviews, questionnaires and ex-
aminations. Details about study design, sampling method,
data collection and response rates have been published
elsewhere [16]. All studies were approved by the
Figure 1 Flow diagram.
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Association and written informed consent was obtained
from all participants.
Lung function measurements and COPD definition
In the first follow-up study (F4), standardized spirometry
was performed using a pneumotachograph-type spirom-
eter (Masterscreen PC, CardinalHealth, Germany). The
spirometer was calibrated at least once a day before
measurements, and additionally, an internal control was
used to ensure constant instrumental conditions. In order
to obtain a minimum of two acceptable and reproducible
values, participants performed at least three forced expira-
tory lung function manoeuvers. Spirometric measure-
ments were in line with the ATS guidelines. Airflow
limitation was defined as a pre-bronchodilator FEV1/FVC
below the lower limit of normal (LLN). Predicted values
were calculated from reference equations provided by the
Global Lung Function Initiative [17]. Participants with a
FEV1/FVC ratio ≥ LLN were defined as the non-COPD
group. For sensitivity analyses, airflow limitation was de-
fined as the pre-bronchodilator FEV1/FVC < 0.7 following
modified GOLD criteria [18].In both definitions, those classified as having airflow
limitation were sub-classified as grade 1 with FEV1%
pred. ≥ 80, grade 2 with 50 ≤ FEV1% pred. < 80, grade 3
with 30 ≤ FEV1% pred. < 50 and grade 4 with FEV1%
pred. < 30. Only 1 participant showed grade 3 airflow
limitation and was grouped into grade 2+ for analysis.
There were no observations in grade 4.Health-related quality of life
HRQL information was collected in all three visits, i.e.
over a ten year period lasting from 7 years before the
lung function test to 3 years after the lung function test.
HRQL was assessed using the generic Short Form 12
Health Survey Questionnaire (SF-12) which consists of
12 items selected from the SF-36 [19]. The questionnaire
has well-documented reliability and validity and provides
the physical and mental health summaries (PCS-12,
MCS-12) as two summary scores [20]. The scores yield a
mean score of 50 and a standard deviation of 10 in the
general U.S. population with higher values indicating
better health. A HRQL difference of about three points
can be seen as clinically relevant [21].
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in the F4 and F4L studies at the study center and com-
pleteness was checked by the study personnel. In the S4
study, the SF-12 questionnaire was integrated into the
examination interview.
Co-variables
In standardized computer-assisted face-to-face interviews
and in additionally administered questionnaires, informa-
tion on age, sex, school education (basic (≤9 years), sec-
ondary (10–11 years) and higher (≥12 years)), smoking
status (current, former and never smoker (self-reports
were compared with previous or following information on
smoking status)), and self-reported data on the presence
of a number of comorbidities were collected.
The following comorbid conditions were included as
binary covariates as they have been shown to be associated
with COPD [3,4] and may influence HRQL [22]: heart fail-
ure, myocardial infarction, stroke, cancer and diabetes.
For cancer and myocardial infarction, participants were
asked if they were ever diagnosed with these diseases by a
physician. For heart failure, this question was restricted to
the last 12 months. Participants were also asked if they
had ever been treated for a stroke in a hospital. Diabetes
was defined as a physician-diagnosed history of diabetes
or the intake of hypoglycemic drugs according to the ATC
code A10. Furthermore, BMI (weight in kilograms/height
squared in meters obtained by standardized medical
examination by trained medical staff ) was included in
order to account for possible weight differences. Finally,
participants were asked if they had ever had a physician
diagnosis of chronic bronchitis, COPD or emphysema.
Statistical analyses
Of 1,321 participants with complete lung function data
1,291 had complete HRQL data at the time of the lung
function test (F4) and in the previous study S4 and
1,017 three years later at F4L. For participants with
missing information on education (n = 3), the most fre-
quent category (low education) was assumed, and for
three participants with missing information on BMI,
BMI data from the previous or following examination
was assumed. Five participants had missing information
on heart failure and were excluded from the extended
analysis considering comorbidities.
Characteristics of participants in different COPD grades
and without COPD in the F4 examination as well as un-
adjusted values for PCS-12 and MCS-12 were compared
using analysis of variance (ANOVA) for continuous vari-
ables and Chi2-tests or Fisher’s exact tests for categorical
variables.
In order to estimate the effect of airflow limitation on
past, present and future HRQL, regression analyses with
HRQL as the dependent variable were performed usinglinear mixed models with random intercepts. These
models are a repeated measurement method that can deal
with different numbers of observations per subject. They
do not exclude patients with missing S4 or F4L data but
use the available information before drop-out to estimate
means and covariances. By accounting for within-patient
correlations, appropriate adjustments for parameter esti-
mates are made at times when data are incomplete [23].
Regression models were adjusted for age, sex and
school education in basic models and in addition for
smoking status, five selected comorbidities and BMI in
extended models. Comorbidities, smoking status and
BMI were time-varying while COPD grade, age at F4,
sex and education were constant. The variance of the
random intercept distribution was used to assess hetero-
geneity of mean HRQL levels between subjects.
Analyses were performed using the SAS software
(SAS Institute Inc., Cary, NC, USA, Version 9.3) pack-
age. P-values of 0.05 or less were considered statistically
significant.
Sensitivity analyses
For sensitivity analyses, FEV1 and the FEV1/FVC ratio as
well as their interactions with time were considered as
continuous variables instead of the COPD grade.
In order to investigate a potential misclassification,
additional sensitivity analyses were performed excluding
asthmatic subjects from the COPD group. First, subjects
who showed an airflow limitation without having a phys-
ician diagnosis of COPD but who reported at the time of
the lung function test an asthma attack in the last
12 months (n = 4) were excluded. Second, subjects with
airflow limitation who reported a history of asthma but
no physician diagnosis of COPD (n = 15) were excluded.
Furthermore, a previous history of asthma was consid-
ered in the extended model as a further comorbidity.
Results
In all, 101 or 7.8% of the 1,291 participants with valid
lung function test and complete HRQL data were classi-
fied as having an airflow limitation in the F4 study. Of
these, 59.4% were in grade 1. The majority of COPD
cases found by spirometry were undiagnosed before:
20% of participants with COPD grade 1 reported a phys-
ician diagnosis of chronic bronchitis, COPD or emphy-
sema and 45% of the grade 2+ group.
Characteristics of subjects at the time of the lung func-
tion test are shown in Table 1. Groups with different
grades of airflow limitation differed significantly regarding
age and smoking status, while there were no differences as
to sex, educational level, BMI and comorbidities.
Without adjusting for covariates, participants with
COPD grade 1 or 2+ showed lower physical scores (PCS-
12) than the non-COPD group (47.8/44.2 compared to
Table 1 Characteristics of participants at the time of lung function test (F4 study)
Total No COPD COPD grade 1 COPD grade 2+ p-value
n = 1321 n = 1220 n = 60 n = 41
Age (years) 51.6 (5.7) 51.6 (5.7) 50.0 (5.7) 52.9 (6.3) 0.04a
Female sex 703 (53.2%) 648 (53.1%) 34 (56.7%) 21 (51.2%) 0.83b
Educational level:
Basic 635 (48.1%) 579 (47.5%) 30 (50.0%) 26 (63.4%) 0.16b
Secondary 343 (26.0%) 318 (26.1%) 14 (23.3%) 11 (26.8%)
High 343 (26.0%) 323 (26.5%) 16 (26.7%) 4 (9.8%)
Smoking status:
Never smoker 477 (36.1%) 462 (37.9%) 10 (16.7%) 5 (12.2%) <0.0001b
Current smoker 306 (23.2%) 264 (21.6%) 23 (38.3%) 19 (46.3%)
Former smoker 538 (40.7%) 494 (40.5%) 27 (45.0%) 17 (41.5%)
Body mass index (kg/m2):
Normal (18.5≤ BMI < 25) 455 (34.4%) 410 (33.6%) 31 (51.7%) 14 (34.2%) 0.11c
Underweight (BMI < 18.5) 4 (0.3%) 4 (0.3%) 0 (0.0%) 0 (0.0%)
Overweight (25 ≤ BMI < 30) 520 (39.4%) 482 (39.5%) 21 (35.0%) 17 (41.5%)
Obese (BMI > 30) 342 (25.9%) 324 (26.6%) 8 (13.3%) 10 (24.4%)
Comorbid conditions:
Heart failure (nmiss = 7) 15 (1.1%) 13 (1.1%) 2 (3.3%) 0 (0.0%) 0.22c
Myocardial infarction 22 (1.7%) 22 (1.8%) 0 (0.0%) 0 (0.0%) 0.81c
Stroke 14 (1.1%) 13 (1.1%) 1 (1.7%) 0 (0.0%) 0.67c
Cancer 62 (4.7%) 57 (4.7%) 5 (8.3%) 0 (0.0%) 0.16c
Diabetes 50 (3.8%) 48 (3.9%) 2 (3.3%) 0 (0.0%) 0.57c
Data are mean (standard deviation) or n (%).
abased on ANOVA bbased on Chi2-test cbased on Fishers exact test.
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(Table 2). This difference was also apparent seven years
before and three years after spirometry. The physical score
decreased slightly over time in all COPD groups as in con-
trols. No group differences were observed with respect to
the mental SF-12 score (MCS-12) neither at the time of
spirometry nor in the previous (S4-study) or following
study (F4L-study).Table 2 Unadjusted analysis of the physical and mental comp
spirometry, seven years before and three years later
Total No COPD
PCS-12
S4 (−7 years) 48.87 (8.22) 49.05 (8.03)
F4 (baseline) 48.57 (8.66) 48.75 (8.52)
F4L (+3 years) 48.45 (8.64) 48.59 (8.61)
MCS-12
S4 (−7 years) 50.65 (9.14) 50.63 (9.13)
F4 (baseline) 50.72 (9.22) 50.70 (9.25)
F4L (+3 years) 51.57 (9.32) 51.61 (9.26)
PCS-12: Physical Component Score, MCS-12: Mental Component Score.
abased on ANOVA.Linear mixed models showed a significant negative
effect of COPD grade 2+ on PCS-12 of −3.5 points
(p = 0.008) at the time of spirometry (Table 3). This effect
persisted (−4.0 points, p = 0.003) when comorbidities were
considered in the extended model. There was a small, but
insignificant negative effect of COPD grade 1 in both
models (−1.1/-1.1 points). Interaction terms of COPD and
time, representing the longitudinal effect of COPD ononent score (PCS-12 and MCS-12) of the SF-12 at time of
COPD grade 1 COPD grade 2+ p-valuea
48.09 (8.50) 44.84 (11.85) 0.002
47.83 (9.60) 44.23 (10.30) 0.004
47.88 (8.79) 44.16 (8.74) 0.029
50.24 (8.37) 51.83 (10.66) 0.607
50.44 (8.81) 51.98 (9.02) 0.672
50.75 (9.59) 51.40 (11.21) 0.799
Table 3 Regression analysis: linear mixed models
Effect Physical component: PCS-12 Mental component: MCS-12
Basic model Extended model Basic model Extended model
No COPD ref. ref. ref. ref.
COPD grade 1 −1.10 −1.10 −0.10 0.16
COPD grade 2+ −3.54** −3.98** 1.24 1.36
Time (1, F4L)*no COPD ref. ref. ref. ref.
Time (1, F4L)*COPD grade 1 0.15 −0.26 −0.66 −0.94
Time (1, F4L)*COPD grade 2+ −1.16 −1.08 −0.75 −0.71
Time (−1, S4)*no COPD ref. ref. ref. ref.
Time (−1, S4)*COPD grade 1 −0.06 −0.18 −0.12 −0.12
Time (−1, S4)*COPD grade 2+ 0.27 0.65 −0.23 −0.02
Time (0, F4) ref. ref. ref. ref.
Time (−1, S4) 0.32 0.08 −0.08 −0.09
Time (1, F4L) −0.33 −0.15 0.73* 0.77*
Age 41–45 yrs. ref. ref. ref. ref.
Age 46–50 yrs. 0.48 0.51 0.83 0.81
Age 51–55 yrs. −1.04 −0.62 0.27 0.29
Age≥ 56 yrs. −2.94*** −2.42*** 0.66 0.68
Sex: male ref. ref. ref. ref.
Sex: female −0.78* −1.00** −2.33*** −2.48***
Educational level:
Basic education ref. ref. ref. ref.
Secondary education 1.61*** 1.20** −0.66 −0.70
High education 2.40*** 1.85*** −0.29 −0.44
Smoking status:
Never smoker ref. ref.
Current smoker −0.82* −1.05*
Former smoker −0.92 −0.56
BMI:
Normal (18.5≤ BMI < 25) ref. ref.
Underweight (BMI < 18.5) −0.60 −1.75
Overweight (25≤ BMI < 30) −0.48 −0.34
Obese (BMI > 30) −2.48*** 0.25
Comorbidities:
Heart failure −4.94*** −2.75*




Intercept 49.12 50.64 51.71 52.26
*p < 0.05, **p < 0.01, ***p < 0.001.
S4: −7 years, F4: baseline, F4L: +3 years.
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extended model. In the extended model, the dimension of
the negative association of obesity, heart failure, myocar-
dial infarction, stroke and cancer with PCS-12 was similarto the effect of COPD grade 2+. Regarding MCS-12, no
significant associations with COPD were found.
Resulting adjusted mean PCS-12 and MCS-12 scores
are shown in Figure 2. At the time of spirometry (F4),
Figure 2 Adjusted mean PCS-12 and MCS-12 scores at S4, F4, F4L.
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COPD grade 1/grade 2+ group and 48.7 for participants
without airflow limitation. For MCS-12, adjusted mean
scores were 50.6/51.9 and 50.7, respectively.
Mean PCS-12 scores for the COPD grade 2+ group
were significantly (p < 0.05) reduced in every study (−3.5
in F4, −3.3 in S4 and −4.7 in F4L) compared with thegroup without airflow limitation. This difference per-
sisted even when comorbidities were considered in the
extended model.
Regarding longitudinal changes over time, a small de-
cline in the physical score was observed in all groups.
The decline over ten years was significant in the refer-
ence group, but not in the COPD grade 1 and 2+ groups
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the ten year increase in MCS-12 was significant in the
group without airflow limitation, but not in the COPD
groups. Consideration of comorbidities hardly changed
the adjusted mean PCS-12 and MCS-12.
The variance of random intercepts ranged from 27.5
(SE 1.7) to 31.7 (SE 2.1), indicating a high degree of het-
erogeneity in mean HRQL levels between individuals.
Using the GOLD definition as an alternative approach
to define COPD resulted in a COPD prevalence of 10%
(n = 132), with 62.9% of cases classified as grade 1. PCS-
12 estimates for COPD grade 2+ were smaller than ac-
cording to the LLN definition. Estimates for COPD
grade 1 hardly changed and were still insignificant.
MCS-12 estimates as well as longitudinal associations
remained insignificant (Additional file 1: Appendix Table
A1-A4).Sensitivity analyses
When considering FEV1% pred. as a continuous variable
instead of the COPD groups, there was a significant posi-
tive effect of FEV1% pred. on PCS-12 (β = 0.077, p < 0.001),
but not on MCS-12. All interaction terms between FEV1%
pred. and time (S4, F4, F4L) were insignificant. When con-
sidering the FEV1/FVC ratio as a continuous variable, the
effect on PCS-12 was insignificant (β = 0.072, p = 0.057).
Neither the effect on MCS-12 nor the interaction terms
with time were significant.
The proportion of participants reporting a history of
asthma is larger in the COPD group (30.7%) than in con-
trols (7.5%). Nevertheless, a high proportion of COPD
cases reporting a previous history of asthma also report a
physician diagnosis of COPD (51.6%). Only 4 COPD cases
reported no physician diagnosis of COPD but asthma
symptoms in the last 12 months. Excluding these subjects
did not change parameter estimates and adjusted PCS-12
and MCS-12 means. Excluding 15 subjects who reported
a previous history of asthma and no physician diagnosis of
COPD increased the cross-sectional effect of COPD grade
2+ from 3.5 to 5.2 (p = 0.001), but did not change the ef-
fect of COPD grade 1 or the insignificant longitudinal ef-
fects of COPD.
Considering a previous history of asthma in the ex-
tended regression models slightly reduced the effect of
COPD grade 2+ on PCS-12 from −4.0 to −3.5 points but
did not change estimates for MCS-12.Discussion
The objective of this study was to examine time trends
in HRQL over ten years of middle-aged persons with
early COPD stages compared to controls without airflow
limitation and to quantify the effect of COPD under
consideration of common COPD-related comorbidities.We found a clinically relevant, negative cross-sectional
association of COPD grade 2+ with the physical aspects
of HRQL, but no significant effects of grade 1. The effect
of grade 2+ was not confounded by common COPD co-
morbidities. In the longitudinal perspective of ten years
there were no significant effects of COPD on HRQL. A
somewhat more pronounced decrease in physical health
over 10 years was observed in participants with COPD
grade 2+, but this decrease was not statistically signifi-
cant. Regarding mental aspects of HRQL, we found a
slight increase over time for all participants. This in-
crease was smaller in both COPD groups compared to
the group without airflow limitation. Although all longi-
tudinal changes found here were small, results indicate
that disease progression from early to higher COPD
grades implies loss in HRQL. Therefore, efficient inter-
ventions that slow disease progression, such as smoking
cessation approaches, are not only clinically but also
from the perspective of quality of life very reasonable at
early stages of disease [24,25]. Our results are in accord-
ance with previous studies which found a negative rela-
tionship between HRQL and COPD which increases
with disease severity [12,26-30]. A number of them were
also performed in a general population setting and used
the generic SF-12 or SF-36 instrument for HRQL mea-
surements [12,26,27].
Based on data from the large international Burden of
Obstructive Lung Disease (BOLD) study, a recent cross-
sectional analysis by Janson et al. investigated the impact
of COPD on health status as measured by the SF-12
[12]. The population-based setting of this epidemiologic
study was comparable to our analysis. Estimates for
physical health found in this study were very similar to
our results: Grade 2 COPD according to the LLN defin-
ition was associated with a reduction of −3.2 points of
PCS-12 while estimates for grade 1 were not significant.
However, BOLD reported significant negative associa-
tions between COPD grade 2 and higher and the mental
SF-12 score which could not be confirmed in our study.
Similar to our analysis, effect estimates were slightly
stronger using the LLN definition compared with the
GOLD staging (−3.2 vs. -3.0 for grade 2). The associa-
tions between COPD and HRQL found by Janson et al.
persisted independent of four common comorbidities
(heart disease, hypertension, diabetes and stroke). In our
extended analysis considering similar comorbidities, the
effect of COPD grade 2+ was also significant and of
similar size to the basic model without comorbidities.
A population-based study from Norway also reported
a negative association of COPD with SF-12 physical
scores [26]. Grade 2 was associated with a −3.1 reduc-
tion of PCS-12, while estimates for grade 1 and regard-
ing MSC-12 were not significant. DiBonventure et al.
described negative effects of COPD on both MCS-12
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[29]. As this analysis used self-reported information on
COPD diagnosis without lung function measurement
the reason for stronger effects on HRQL may be the fact
that undiagnosed COPD patients were not considered.
Bridevaux et al. also focused on early COPD stages
identified in a population-based sample and found that
subjects in COPD stage 1 with respiratory symptoms
had lower PCS scores than the reference category while
asymptomatic subjects with stage 1 COPD showed simi-
lar PCS scores to the reference group [31]. For MCS, no
differences were observed for COPD in stage 1.
Regarding common COPD-related comorbidities, only
a few studies focused on the relationship of COPD and
HRQL in COPD patients while considering comorbid
conditions.
In a study on previously diagnosed COPD patients using
the SF-36, van Manen et al. reported that impairments in
physical functioning, in role functioning due to physical
problems and in vitality were related both to COPD and
comorbidity, whereas social functioning, mental health
and role functioning due to emotional problems were un-
related to COPD [32]. However, comorbidity was consid-
ered as a dummy variable together with an interaction
with COPD. Therefore, the individual effect of single co-
morbid conditions was not provided.
Burgel et al. found in a clinical cohort of stable COPD
patients that dyspnea, exacerbations and depression
were important determinants of disease-specific HRQL
while the degree of airflow limitation, low BMI and cor-
onary arterial disease had only a modest impact and
other cardiovascular conditions, obesity and diabetes
showed no significant impact on HRQL [22]. However,
as this study used a disease-specific HRQL instrument
some effects of comorbid conditions on HRQL may not
have been captured.
Only a few studies have investigated COPD-related
changes in HRQL over time. Most of these studies fo-
cused on HRQL changes of hospitalized patients (e.g.
during acute exacerbations [33,34]), newly detected
COPD cases [35], patients in the end-stage setting [15]
or observed HRQL changes after pharmacological and
non-pharmacological interventions [13,14]. In general,
weak associations between changes in lung function and
HRQL developments were found [36,37].
Koskela et al. assessed HRQL as measured by the gen-
eric 15D questionnaire over 4 years in elderly COPD pa-
tients recruited from two university hospitals in Finland
and found that the majority of them showed declining
HRQL over time. A clinically relevant deterioration was
observed within 1.7 years in this patient group [38].
Marin et al. observed changes in health status as mea-
sured by the disease-specific SGRQ in a cohort of COPD
patients over ten years and found that SGRQ scoresworsen with increasing COPD severity [39]. Oga et al.
examined both the course of disease specific HRQL and
of lung function in stable COPD patients within three
years [36]. They observed a small decline in HRQL over
time, but found that changes in health status were not
correlated with changes in lung function.
As these previous longitudinal studies use data from
clinical COPD patients without comparison to controls
without airflow limitation, their results are not directly
transferable to COPD patients found in a younger gen-
eral population sample with a high percentage of un-
diagnosed cases.
One strength of our study is that it is based on data
from a general population cohort and therefore may
yield results for early stages of COPD that are more
generalizable than those from clinical cohorts. Although
patient recruitment from physicians or clinics can be ex-
pected to result in an unbiased sample for those with se-
vere or very severe COPD, mild or moderate disease
stages which are often undiagnosed, are commonly un-
derrepresented [40]. However, it is important to address
early stages of COPD as confirmed in a previous
population-based study where patients with undiagnosed
COPD also showed impaired HRQL compared to partic-
ipants without COPD [41]. Furthermore, the longitu-
dinal character of our analysis allowed us to address the
scarcely investigated question of HRQL changes over
time in early disease stages.
One limitation of the study is a possible selection bias.
As it has to be expected that non-participants of all
three surveys used are more impaired than participants,
the study sample may not be representative for
Germany. Although this bias is likely to be less pro-
nounced in the early disease stages we focus on, this
problem can still affect both COPD patients and con-
trols. Participants who were lost to follow-up between
F4 and F4L were significantly more frequently smokers
or former smokers, showed more often airflow limitation
and had a lower PCS-12 than participants who took part
in both studies. The main reason of drop-out was refusal
of participation while death and moving out of the study
region were of minor importance. Selection effects could
result in both over- and underestimation of the impact
of COPD, which limits the generalizability of our find-
ings. These effects could also be a reason for the weak
longitudinal effects found in our study which do not re-
flect disease progression over time.
Another potential problem is the limited number of
COPD patients in the sample. The prevalence of COPD
found in our study (7.8% according to LLN/10.0% ac-
cording to the GOLD definition) is slightly lower than
the BOLD estimates for Germany [11]. But comparabil-
ity is limited as the BOLD study also included higher
age groups which have a higher COPD prevalence. A
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(SHIP) also reported a lower COPD prevalence of 7.2%
(defined by the LLN criteria, post-bronchodilator spirom-
etry) but included age groups from 35 to 90 years [42].
In general, there is a large range of COPD prevalence
data in international studies [43,44]. Population-based
studies such as NHANES reported a COPD prevalence
of 14.0% in a U.S. population of 40–59 years [45] while
Maio et al. reported a multinational COPD prevalence
of 10.5% in 40–49 year olds and 12.0% in 50–59 year
olds [46] (both studies used pre-bronchodilator spirom-
etry and LLN definition). However, differences in demo-
graphics, smoking behavior or diagnostic approaches
have to be considered when directly comparing COPD
prevalences.
The limited number of COPD cases in our study, es-
pecially of cases in higher COPD grades, may result in a
low power and failure to detect differences e.g. in the
mental SF-12 score. However, it is also possible that
there really is no difference in MCS-12 in early stages.
This is supported by other studies that also found differ-
ences in PCS, but not in MCS scores either between
GOLD stages [27] or between COPD patients in early
stages and controls [26,30].
Although the asthma and COPD overlap is widely ac-
knowledged, pre-bronchodilator spirometry may misclas-
sify asthmatic subjects as having COPD [47]. Nevertheless,
for simplicity reasons, pre-bronchodilator spirometry is
often performed and accepted in population-based studies
[48]. We considered the possibility of misclassification in
sensitivity analyses but our results barely changed. The
proportion of never smokers in the groups with airflow
limitation is also comparable to or below that reported in
other studies [49,50].
Furthermore, the presence of comorbid conditions was
based on self-report, which may limit the validity of
these data. We could not find increased comorbidity in
COPD cases as described in previous studies [3,4]. This
may be due to the fact that a younger population in early
COPD stages was considered in our analysis while rele-
vant comorbidities may develop predominantly later
with age and COPD progression.
Finally, as we did not have longitudinal lung function
data, further studies are needed to assess the long-term
effects of COPD as well as lung function changes over
time on HRQL development which also include the
whole COPD severity spectrum.
Conclusion
Despite small HRQL differences between COPD patients
in early stages and controls and small changes over a ten
year time period, our results indicate that it is important to
prevent subjects with airflow limitation from disease pro-
gression to more severe grades. Furthermore, awareness ofHRQL impairments in early and even in undiagnosed
stages is vital for early identification of persons at risk
and an efficient therapy at early stages to slow disease
progression and, thus, maintain high HRQL in COPD
patients for as long as possible.
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